William Blair lowered shares of Neumora Therapeutics (NASDAQ:NMRA – Free Report) from an outperform rating to a market ...

Fintel reports that on March 10, 2025, Guggenheim downgraded their outlook for Neumora Therapeutics (NasdaqGS:NMRA) from Buy ...

Robert Lenz is leaving the brain drug developer to “pursue other interests.” Elsewhere, Atara is cutting half of its staff ...

Neumora Therapeutics (NASDAQ:NMRA) fell ~11% in the premarket on Friday as Stifel downgraded the biotech after efficacy concerns prompted J&J (NYSE:JNJ) to discontinue a late-stage program called ...

William Blair downgraded Neumora Therapeutics (NMRA) to Market Perform from Outperform.Discover the Best Stocks and Maximize Your Portfolio: ...

Guggenheim lowered shares of Neumora Therapeutics (NASDAQ:NMRA – Free Report) from a buy rating to a neutral rating in a research note released on Friday morning, Marketbeat.com reports.

About Neumora Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way ...

After failing to hit the primary endpoint in a Phase III trial, Neumora is remixing study parameters in two replicate trials, ...

Analysts say the decision is a “big blow” to a once-promising class of brain therapies that include’s J&J’s aticaprant and a ...

NEW YORK, NY / ACCESS Newswire / March 7, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

KOASTAL-2 and -3 studies optimized based on learnings from KOASTAL-1; topline data expected from KOASTAL-3 in the first quarter of 2026 and -2 in the second quarter of 2026 Topline data from NMRA-511 ...